BioNTech Results Presentation Deck
Third Quarter 2020 Financial Results (unaudited) - Profit and Loss
22
(in millions) ¹
Revenues resulting from collaboration and license
agreements
Revenues from other sales transactions
Total revenues
Cost of sales
Gross profit
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Other operating income less expenses
Finance income less expenses
Income taxes
Loss for the period
1 Numbers have been rounded; numbers presented may not add up precisely to the totals
Three months ended
September 30,
2019
€ 22.2
6.4
€ 28.7
2020
€ 59.6
7.9
€ 67.5
(6.9)
€ 60.6
(227.7)
(4.3)
(23.3)
8.3
(21.1)
(2.5)
€ (210.0)
(4.3)
€ 24.4
(50.4)
(0.7)
(10.6)
0.4
6.8
0.0
€ (30.1)
Nine months ended
September 30,
2019
€ 64.3
16.3
€ 80.6
2020
€ 113.4
23.5
€ 136.9
(18.4)
€ 118.5
(388.0)
(7.7)
(58.0)
8.6
(24.8)
(0.3)
€ (351.7)
(12.9)
€ 67.7
(161.0)
(1.9)
(34.5)
1.2
7.6
0.0
€ (120.9)
BIONTECHView entire presentation